Research
Cellular
There is a risk of excessive reduction in skeletal muscle mass (SMM) with GLP-1-based therapies.
Practitioners should monitor muscle mass in patients using GLP-1 therapies to mitigate risks of sarcopenia.
StrongQualifiesmedium confidence
However, a risk of excessive reduction in skeletal muscle mass (SMM), potentially leading to sarcopenia, could minimize the benefit/risk balance of this pharmacological class.
Why this rating
The claim is based on human studies, indicating strong evidence.
Source
GLP-1-derived therapies and risk of sarcopenia: myth or reality?
André J. Scheen · Expert Opinion on Drug Safety · 2026
DOI 10.1080/14740338.2026.2640980
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →